Summary

The global Polycystic Ovarian Syndrome market is projected to grow from USD 5,839.82 million in 2025 to USD 10,130.72 million by 2035, registering a CAGR of 5.61% during the forecast period. The market growth is driven by rising awareness of PCOS, increasing diagnosis rates, and growing demand for advanced treatment options worldwide.

Increasing Demand for Early and Accurate PCOS Diagnosis
To diagnose polycystic ovarian syndrome (PCOS) accurately and early, which is one of the most important prerequisites for successful treatment, has already become one of the key factors why advanced ultrasound, including image-guided and Doppler ultrasound, is being adopted at such a breakneck pace globally. Newer diagnostic techniques like 3D imaging and Doppler-based assessments that allow clear visualization of ovarian morphology are being used to improve cancer diagnosis, clinical confidence, and patient management outcomes.

Segmentations Insights
By Drug Class
- Oral Contraceptives - Widely prescribed for hormonal cycle regulation.
- Antiandrogens - Help reduce excess androgen-related symptoms.
- Insulin Sensitizing Agents - Improve insulin resistance among PCOS patients.
- Antidepressants - Support mental health and emotional stability.
- Anti-Obesity - Assist in effective long-term weight management.
- Others - Include supportive and combination therapeutic treatments.
By Route of Administration
- Oral - Preferred due to convenience and easy usage.
- Parenteral - Used for targeted and faster drug delivery.
By Distribution Channel
- Hospital Pharmacies - Ensure access to prescribed specialty medications.
- Retail Pharmacies - Provide convenient availability of PCOS treatments.
- Online Pharmacies - Growing rapidly with digital healthcare adoption.

North America dominates the world Polycystic Ovarian Syndrome market due to advanced healthcare infrastructure, strong awareness, and favorable reimbursement policies, while Europe holds on to the steady growth through increased treatment accessibility and government-partnered initiatives. Asia Pacific is setting up to be the fastest-growing region as it is supported by rise in urbanization, increasing diagnosis rates, and expanding healthcare investments.

Expansion of Women’s Health Portfolio
In February 2022, Organon purchased the rights of contraceptive products only from Bayer AG in China including Hong Kong and Macau areas. Also, signing a strategic agreement for Vietnam. Through these actions, the company has significantly enhanced its women's health product line, increased its presence in Asia, and facilitated better regional access to contraceptive products.

Rising Adoption of Point-of-Care Diagnostic Solutions
Presently, the spreading use of Point-of-Care (POC) testing is providing a lucrative strategic opening for the global Polycystic Ovarian Syndrome market since it results in a quicker and easier diagnosis. Portable hormone-testing devices and rapid screening methods are not only increasing early detection rates but are also lessening reliance on centralized laboratory facilities.

Key Report Attributes
- Market Size 2025: USD 5 ,839.82 Million
- Market Size 2035: USD 10,130.72 Million
- CAGR (2025-2035): 5.61%
- Base Year: 2024
- Market Forecast Period: 2025-2035

Industry Segmentations Growth
- By Drug Class: Oral Contraceptives - 5.78%, Antiandrogens - 4.51%.
- By Route of Administration: Oral - 5.74%, Parenteral - 4.10%.
- By Distribution Channel: Hospital pharmacies - 5.85%, Retail pharmacies - 4.64%.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ........................................... 21
1.1 Overview .......................... 21
1.2 MARKET ATTRACTIVENESS ANALYSIS ......................... 22
1.3 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS ........ 23
1.4 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION ........................... 24
1.5 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL ................................. 25
1.6 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY REGION ................ 26
2 MARKET INTRODUCTION ....................................... 28
2.1 DEFINITION ...................... 28
2.2 SCOPE OF THE STUDY ...... 28
2.3 Research Objective ........... 28
2.4 MARKET STRUCTURE ........ 29
3 RESEARCH METHODOLOGY ................................. 30
3.1 Overview .......................... 30
3.2 DATA flow ........................ 32
3.2.1 DATA MINING PROCESS ...................................... 32
3.3 Purchased Database: ........ 33
3.4 Secondary Sources: .......... 34
3.4.1 SECONDARY RESEARCH DATA FLOW: .................. 35
3.5 Primary Research: ............ 36
3.5.1 PRIMARY RESEARCH DATA FLOW: ...................... 37
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ......................... 38
3.6 Approaches for market size estimation: ........................ 39
3.6.1 REVENUE ANALYSIS APPROACH .......................... 39
3.7 Data forecasting ............... 39
3.7.1 DATA FORECASTING TYPE ................................... 40
3.8 Data modeling .................. 41
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ................. 41
3.8.2 DATA MODELING: ..... 42
3.9 Teams and Analyst Contribution ................................... 44
4 MARKET DYNAMICS ............................................... 46
4.1 INTRODUCTION ................ 46
4.2 Drivers ............................. 47
4.2.1 RISING PREVALENCE OF INSULIN RESISTANCE & METABOLIC COMORBIDITIES ........................................... 47
4.2.2 IMPROVED ULTRASOUND TECHNOLOGY .............. 47
4.2.3 THE "INOSITOL" BOOM ........................................ 48
4.2.4 EXPANDING THERAPEUTIC SCOPE BEYOND REPRODUCTIVE SYMPTOMS ......... 48
4.3 Restraints ........................ 49
4.3.1 THE "THIN PCOS" PARADOX ................................ 49
4.3.2 LACK OF STANDARDIZED, CURATIVE TREATMENT ........................................... 50
4.3.3 HIGH ATTRITION IN CLINICAL TRIALS .................. 50
4.4 Opportunities ................... 51
4.4.1 TELEHEALTH SPECIALIZATION ............................ 51
4.4.2 POINT-OF-CARE (POC) TESTING ........................... 52
5 MARKET FACTOR ANALYSIS ................................. 53
5.1 Regulatory Environment & Compliance .......................... 53
5.2 Technological Trends & Innovation ............................... 54
5.3 Patient Demographics & Disease Burdens ..................... 55
5.4 Pricing Analysis & Reimbursement Dynamics ................ 56
5.4.1 PRICING ANALYSIS .............................................. 56
5.4.1.1 NORTH AMERICA ..... 56
5.4.1.2 EUROPE ................. 56
5.4.1.3 ASIA PACIFIC ......... 56
5.4.1.4 LATIN AMERICA ...... 56
5.4.1.5 MIDDLE EAST & AFRICA ....................................... 57
5.4.2 REIMBURSEMENT DYNAMICS .............................. 57
5.5 Market Entry & Exit Barriers .......................................... 58
5.5.1 BARRIERS TO ENTRY ........................................... 58
5.5.2 BARRIERS TO EXIT ............................................... 58
5.6 Partnerships & Collaborations ...................................... 59
5.7 Consumer & Healthcare Provider Preferences ............... 60
5.7.1 CONSUMER PREFERENCES .................................. 60
5.7.2 HEALTHCARE PROVIDER PREFERENCES ............... 60
5.8 PESTLE ANALYSIS ............ 60
5.8.1 POLITICAL FACTORS ........................................... 60
5.8.2 ECONOMIC FACTORS .......................................... 60
5.8.3 SOCIAL FACTORS ..... 61
5.8.4 TECHNOLOGICAL FACTORS ................................. 61
5.8.5 LEGAL FACTORS ...... 61
5.8.6 ENVIRONMENTAL FACTORS ................................ 61
5.9 Porter's Five Forces Model ........................................... 62
5.9.1 THREAT OF NEW ENTRANTS ................................ 63
5.9.2 BARGAINING POWER OF SUPPLIERS .................... 63
5.9.3 BARGAINING POWER OF BUYERS ......................... 63
5.9.4 THREAT OF SUBSTITUTES ................................... 63
5.9.5 INTENSITY OF RIVALRY ....................................... 63
5.10 Product Pipeline Analysis ............................................. 64
5.11 Case Study Analysis ......... 65
5.12 Investment & Funding Scenarios ................................... 66
5.13 Post-Market Surveillance & Safety Data ........................ 67
5.14 disease overview .............. 68
5.15 diagnosis ......................... 69
5.16 CURRENT TREATMENT ..... 70
6 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS .............................. 72
6.1 Overview .......................... 72
7 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION ... 76
7.1 Overview .......................... 76
8 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL ......... 78
8.1 Overview .......................... 78
9 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY REGION ....................................... 81
9.1 Overview .......................... 81
9.2 North America .................. 83
9.2.1 US ........................... 88
9.2.2 CANADA .................. 90
9.3 europe ............................. 92
9.3.1 GERMANY ................ 97
9.3.2 UK ........................... 99
9.3.3 FRANCE ................... 101
9.3.4 NETHERLANDS ......... 103
9.3.5 ITALY ....................... 105
9.3.6 SPAIN ...................... 107
9.3.7 REST OF EUROPE ...... 109
9.4 ASIA-PACIFIC ................... 111
9.4.1 CHINA ...................... 116
9.4.2 INDIA ....................... 118
9.4.3 JAPAN ..................... 120
9.4.4 SOUTH KOREA .......... 122
9.4.5 MALAYSIA ............... 124
9.4.6 THAILAND ................ 126
9.4.7 INDONESIA .............. 128
9.4.8 REST OF APAC ......... 130
9.5 LATIN america ................. 132
9.5.1 BRAZIL ..................... 137
9.5.2 MEXICO ................... 139
9.5.3 ARGENTINA ............. 141
9.5.4 REST OF LATIN AMERICA ..................................... 143
9.6 iddle east & africa ............. 145
9.6.1 GCC COUNTRIES ...... 150
9.6.2 SOUTH AFRICA ......... 152
9.6.3 REST OF MEA ........... 154
10 COMPETITIVE LANDSCAPE ................................... 157
10.1 Introduction ..................... 157
10.2 Market Share Analysis, 2025 ........................................ 157
10.3 competitor dashboard ....... 158
10.4 Public Players Stock Summary ..................................... 159
10.5 Comparative Analysis: Key Players Financial ................. 159
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ............. 160
10.6.1 ACQUISITION ........... 160
10.6.2 STRATEGIC ALLIANCE ......................................... 160
11 COMPANY PROFILES ............................................. 161
11.1 Bayer AG .......................... 161
11.1.1 COMPANY OVERVIEW .......................................... 161
11.1.2 FINANCIAL OVERVIEW ......................................... 162
11.1.3 PRODUCTS OFFERED ........................................... 163
11.1.4 KEY DEVELOPMENTS .......................................... 163
11.1.5 SWOT ANALYSIS ...... 164
11.1.6 KEY STRATEGIES ...... 165
11.2 Pfizer Inc. ........................ 166
11.2.1 COMPANY OVERVIEW .......................................... 166
11.2.2 FINANCIAL OVERVIEW ......................................... 167
11.2.3 PRODUCTS OFFERED ........................................... 168
11.2.4 KEY DEVELOPMENTS .......................................... 168
11.2.5 SWOT ANALYSIS ...... 168
11.2.6 KEY STRATEGIES ...... 169
11.3 Sanofi .............................. 170
11.3.1 COMPANY OVERVIEW .......................................... 170
11.3.2 FINANCIAL OVERVIEW ......................................... 171
11.3.3 PRODUCTS OFFERED ........................................... 172
11.3.4 KEY DEVELOPMENTS .......................................... 172
11.3.5 SWOT ANALYSIS ...... 172
11.3.6 KEY STRATEGY ......... 173
11.4 AstraZeneca ..................... 174
11.4.1 COMPANY OVERVIEW .......................................... 174
11.4.2 FINANCIAL OVERVIEW ......................................... 175
11.4.4 KEY DEVELOPMENTS .......................................... 176
11.4.5 KEY STRATEGIES ...... 176
11.5 Ferring Pharmaceuticals .............................................. 177
11.5.1 COMPANY OVERVIEW .......................................... 177
11.5.2 FINANCIAL OVERVIEW ......................................... 178
11.5.3 PRODUCTS OFFERED ........................................... 179
11.5.4 KEY DEVELOPMENTS .......................................... 179
11.5.5 KEY STRATEGIES ...... 179
11.6 Theramex ......................... 180
11.6.1 COMPANY OVERVIEW .......................................... 180
11.6.2 FINANCIAL OVERVIEW ......................................... 180
11.6.3 PRODUCTS OFFERED ........................................... 181
11.6.4 KEY DEVELOPMENTS .......................................... 181
11.6.5 KEY STRATEGIES ...... 181
11.7 Teva Pharmaceutical Industries Ltd. ............................. 182
11.7.1 COMPANY OVERVIEW .......................................... 182
11.7.2 FINANCIAL OVERVIEW ......................................... 183
11.7.3 DEVELOPMENTS ...... 184
11.7.4 KEY DEVELOPMENTS .......................................... 184
11.7.5 SWOT ANALYSIS ...... 184
11.7.6 KEY STRATEGIES ...... 185
11.8 Merck KGgA ..................... 186
11.8.1 COMPANY OVERVIEW .......................................... 186
11.8.2 FINANCIAL OVERVIEW ......................................... 187
11.8.3 DEVELOPMENTS ...... 188
11.8.4 KEY DEVELOPMENTS .......................................... 188
11.8.5 SWOT ANALYSIS ...... 188
11.8.6 KEY STRATEGIES ...... 189
11.9 Organon ........................... 190
11.9.1 COMPANY OVERVIEW .......................................... 190
11.9.2 FINANCIAL OVERVIEW ......................................... 191
11.9.3 DEVELOPMENTS ...... 192
11.9.4 KEY DEVELOPMENTS .......................................... 192
11.9.5 KEY STRATEGIES ...... 192
11.10 Novo Nordisk A/S ............. 193
11.10.1 COMPANY OVERVIEW .......................................... 193
11.10.2 FINANCIAL OVERVIEW ......................................... 194
11.10.3 DEVELOPMENTS ...... 194
11.10.4 KEY DEVELOPMENTS .......................................... 195
11.10.5 KEY STRATEGIES ...... 195
12 DATA CITATIONS .......... 196

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 43
TABLE 2 PRODUCT PIPELINE 64
TABLE 3 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 73
TABLE 4 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 74
TABLE 5 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 74
TABLE 6 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 77
TABLE 7 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 79
TABLE 8 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY REGION, 2019-2035 (USD MILLION) 82
TABLE 9 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 84
TABLE 10 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 85
TABLE 11 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS,
2019-2035 (USD MILLION) 86
TABLE 12 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 86
TABLE 13 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION,
2019-2035 (USD MILLION) 87
TABLE 14 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 87
TABLE 15 US POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 88
TABLE 16 US POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 88
TABLE 17 US POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 89
TABLE 18 US POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 89
TABLE 19 US POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 89
TABLE 20 CANADA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 90
TABLE 21 CANADA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 90
TABLE 22 CANADA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 91
TABLE 23 CANADA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 91
TABLE 24 CANADA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 91
TABLE 25 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 93
TABLE 26 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 94
TABLE 27 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 95
TABLE 28 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 95
TABLE 29 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 95
TABLE 30 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 96
TABLE 31 GERMANY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 97
TABLE 32 GERMANY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 97
TABLE 33 GERMANY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 98
TABLE 34 GERMANY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 98
TABLE 35 GERMANY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 98
TABLE 36 UK POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 99
TABLE 37 UK POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 99
TABLE 38 UK POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 100
TABLE 39 UK POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 100
TABLE 40 UK POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 100
TABLE 41 FRANCE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 101
TABLE 42 FRANCE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 101
TABLE 43 FRANCE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 102
TABLE 44 FRANCE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 102
TABLE 45 FRANCE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 102
TABLE 46 NETHERLANDS POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 103
TABLE 47 NETHERLANDS POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS,
2019-2035 (USD MILLION) 103
TABLE 48 NETHERLANDS POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 104
TABLE 49 NETHERLANDS POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION,
2019-2035 (USD MILLION) 104
TABLE 50 NETHERLANDS POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 104
TABLE 51 ITALY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 105
TABLE 52 ITALY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 105
TABLE 53 ITALY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 106
TABLE 54 ITALY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 106
TABLE 55 ITALY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 106
TABLE 56 SPAIN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 107
TABLE 57 SPAIN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 107
TABLE 58 SPAIN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 108
TABLE 59 SPAIN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 108
TABLE 60 SPAIN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 108
TABLE 61 REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 109
TABLE 62 REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS,
2019-2035 (USD MILLION) 109
TABLE 63 REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 110
TABLE 64 REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION,
2019-2035 (USD MILLION) 110
TABLE 65 REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 110
TABLE 66 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 112
TABLE 67 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 113
TABLE 68 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION)
114
TABLE 69 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 114
TABLE 70 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 114
TABLE 71 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 115
TABLE 72 CHINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 116
TABLE 73 CHINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 116
TABLE 74 CHINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 117
TABLE 75 CHINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 117
TABLE 76 CHINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 117
TABLE 77 INDIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 118
TABLE 78 INDIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 118
TABLE 79 INDIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 119
TABLE 80 INDIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 119
TABLE 81 INDIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 119
TABLE 82 JAPAN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 120
TABLE 83 JAPAN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 120
TABLE 84 JAPAN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 121
TABLE 85 JAPAN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 121
TABLE 86 JAPAN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 121
TABLE 87 SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 122
TABLE 88 SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS,
2019-2035 (USD MILLION) 122
TABLE 89 SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 123
TABLE 90 SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 123
TABLE 91 SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 123
TABLE 92 MALAYSIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 124
TABLE 93 MALAYSIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 124
TABLE 94 MALAYSIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 125
TABLE 95 MALAYSIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 125
TABLE 96 MALAYSIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 125
TABLE 97 THAILAND POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 126
TABLE 98 THAILAND POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 126
TABLE 99 THAILAND POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 127
TABLE 100 THAILAND POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 127
TABLE 101 THAILAND POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 127
TABLE 102 INDONESIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 128
TABLE 103 INDONESIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 128
TABLE 104 INDONESIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 129
TABLE 105 INDONESIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 129
TABLE 106 INDONESIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 129
TABLE 107 REST OF APAC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 130
TABLE 108 REST OF APAC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS,
2019-2035 (USD MILLION) 130
TABLE 109 REST OF APAC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 131
TABLE 110 REST OF APAC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 131
TABLE 111 REST OF APAC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 131
TABLE 112 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 133
TABLE 113 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 134
TABLE 114 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS,
2019-2035 (USD MILLION) 135
TABLE 115 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 135
TABLE 116 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION,
2019-2035 (USD MILLION) 136
TABLE 117 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 136
TABLE 118 BRAZIL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 137
TABLE 119 BRAZIL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 137
TABLE 120 BRAZIL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 138
TABLE 121 BRAZIL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 138
TABLE 122 BRAZIL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 138
TABLE 123 MEXICO POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 139
TABLE 124 MEXICO POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 139
TABLE 125 MEXICO POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 140
TABLE 126 MEXICO POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 140
TABLE 127 MEXICO POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 140
TABLE 128 ARGENTINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 141
TABLE 129 ARGENTINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 141
TABLE 130 ARGENTINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 142
TABLE 131 ARGENTINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 142
TABLE 132 ARGENTINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 142
TABLE 133 REST OF LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 143
TABLE 134 REST OF LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD
MILLION) 143
TABLE 135 REST OF LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 144
TABLE 136 REST OF LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD
MILLION) 144
TABLE 137 REST OF LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD
MILLION) 144
TABLE 138 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 147
TABLE 139 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 148
TABLE 140 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD
MILLION) 148
TABLE 141 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 149
TABLE 142 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD
MILLION) 149
TABLE 143 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL,
2019-2035 (USD MILLION) 149
TABLE 144 GCC COUNTRIES POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 150
TABLE 145 GCC COUNTRIES POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS,
2019-2035 (USD MILLION) 150
TABLE 146 GCC COUNTRIES POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 151
TABLE 147 GCC COUNTRIES POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION,
2019-2035 (USD MILLION) 151
TABLE 148 GCC COUNTRIES POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 151
TABLE 149 SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 152
TABLE 150 SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS,
2019-2035 (USD MILLION) 152
TABLE 151 SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 153
TABLE 152 SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION,
2019-2035 (USD MILLION) 153
TABLE 153 SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 153
TABLE 154 REST OF MEA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 154
TABLE 155 REST OF MEA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS,
2019-2035 (USD MILLION) 154
TABLE 156 REST OF MEA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 155
TABLE 157 REST OF MEA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 155
TABLE 158 REST OF MEA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 155
TABLE 159 ACQUISITION 160
TABLE 160 STRATEGIC ALLIANCE 160
TABLE 161 BAYER AG: PRODUCT OFFERED 163
TABLE 162 BAYER AG: KEY DEVELOPMENTS 163
TABLE 163 PFIZER INC.: PRODUCTS OFFERED 168
TABLE 164 SANOFI.: PRODUCTS OFFERED 172
TABLE 166 FERRING PHARMACEUTICALS: PRODUCTS OFFERED 179
TABLE 167 THERAMEX: PRODUCTS OFFERED 181
TABLE 168 THERAMEX: KEY DEVELOPMENTS 181
TABLE 169 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED 184
TABLE 170 MERCK KGAA: PRODUCTS OFFERED 188
TABLE 171 ORGANON: PRODUCTS OFFERED 192
TABLE 172 ORGANON: KEY DEVELOPMENT 192
TABLE 173 NOVO NORDISK A/S: PRODUCTS OFFERED 194